Drugs / Lomustine
Lomustine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GLEOSTINE | — | 1976-08-04 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 1976
1
1
3
4
4
3
3
1
4
2
3
1
2
2
2
1
3
4
2
2
5
3
2
2
3
3
1
3
3
197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05017610 | Oct 2021 → Oct 2022 | gliosarcoma | Emory University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04135807 | Mar 2020 → Jan 2028 expected | anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma | Oliver Jonas | Recruiting | No outcome recorded |
| Phase 0 | NCT02212574 | Apr 2017 → Nov 2018 | medulloblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT07145112 | Oct 2025 → Mar 2027 expected | glioblastoma | University of California, Davis | Recruiting | No outcome recorded |
| Phase 1 | NCT05304663 | Jun 2022 → Dec 2024 | glioblastoma | Philogen S.p.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03425292 | Mar 2018 → Sep 2022 | malignant glioma | Saint John's Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01989052 | May 2014 → Mar 2015 | malignant glioma | Annick Desjardins | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01934361 | Feb 2014 → Jul 2016 | glioblastoma | Novartis Pharmaceuticals | Completed | Mixed |
| Phase 1 | NCT01563614 | Mar 2012 → Nov 2015 | leptomeningeal melanoma | University Hospital, Bonn | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00527657 | Feb 2006 → Feb 2012 | brain neoplasm, melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01682187 | Dec 2005 → May 2012 | glioma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00006024 | Nov 2000 → Jan 2005 | brain glioma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00005796 | Feb 2000 → Jun 2003 | bone marrow disorder, central nervous system neoplasm, chemotherapy-induced toxicity | Indiana University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07811297 | Sep 2026 → Sep 2030 expected | endometrium neoplasm, glioblastoma, ovarian neoplasm, soft tissue sarcoma | Advenchen Pharmaceuticals, LLC. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04573192 | Feb 2021 → Mar 2025 | glioblastoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04421378 | Jun 2020 → Jul 2023 | glioblastoma | Karyopharm Therapeutics Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT02765165 | Apr 2016 → Jul 2020 | glioblastoma | Proximagen Limited | Terminated | No outcome recorded Stop: Business |
| Phase 230 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07632209 | Jun 2026 → Jun 2028 expected | small cell lung carcinoma | Yayi He | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07120984 | Jan 2026 → Jan 2029 expected | glioma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06336291 | May 2024 → Jun 2026 overdue | glioblastoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04863950 | May 2022 → Aug 2026 overdue | glioblastoma | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 2 | NCT04049669 | Oct 2019 → Aug 2026 overdue | diffuse intrinsic pontine glioma, ependymoma, glioblastoma, medulloblastoma | Theodore S. Johnson | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03678883 | Jan 2019 → Jun 2026 overdue | T lymphoblastic leukemia/lymphoma, bone cancer, breast neoplasm, colorectal neoplasm +8 | Actuate Therapeutics Inc. | Active not recruiting | Met primary |
| Phase 2 | NCT03463265 | Aug 2018 → Aug 2022 | glioblastoma | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02724579 | Nov 2017 → Mar 2028 expected | medulloblastoma | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03022578 | Nov 2017 → Feb 2021 | anaplastic astrocytoma, glioblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02986178 | Jun 2017 → Sep 2022 | malignant glioma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01775475 | Sep 2016 → Apr 2021 | diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma, precursor lymphoblastic lymphoma/leukemia | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT01562197 | Apr 2014 → Aug 2018 | glioblastoma | Bart Neyns | Completed | No outcome recorded |
| Phase 2 | NCT01737346 | Oct 2012 → Sep 2013 | glioblastoma | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01582269 | Apr 2012 → Jul 2014 | glioblastoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT01067469 | Jan 2010 → Oct 2016 | brain cancer, glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00989352 | Sep 2009 → Jun 2011 | primary central nervous system lymphoma | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 2 | NCT00293280 | Jul 2005 → Jul 2007 | lung cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00100802 | Mar 2005 → Sep 2012 | anaplastic astrocytoma, gliosarcoma, spinal cord neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00274911 | Feb 2004 → Mar 2010 | central nervous system neoplasm | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00072345 | Jul 2003 → Aug 2004 | cutaneous melanoma, ocular melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00276666 | Nov 2001 → Mar 2010 | central nervous system neoplasm | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00031590 | Apr 2001 → May 2011 | brain cancer, medulloblastoma | Children's Hospital of Philadelphia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00074191 | Jan → Oct 2000 | lymphoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00003929 | Jun 1998 → Mar 2000 | lymphoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00049439 | Mar 1998 → Oct 2005 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003101 | Aug 1997 → Jan 2002 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003113 | Jul 1997 → Dec 2002 | lymphoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00003114 | Jul 1997 → Jun 2002 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002806 | Jul 1996 → Jan 2003 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT02066220 | Jun 2014 → Dec 2026 expected | brain cancer | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00003375 | Oct 1998 → Aug 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | Met primary |
| Phase 319 trials · 3 met primary · 5 missed | ||||||
| Phase 3 | NCT07100730 | Nov 2025 → Jul 2027 expected | adult glioblastoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06419946 | Feb 2025 → Dec 2031 expected | IDH-wildtype glioblastoma | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 3 | NCT05095376 | Mar 2022 → Feb 2026 overdue | gliosarcoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05331521 | Apr 2021 → Mar 2033 expected | oligodendroglioma | University Hospital Heidelberg | Recruiting | No outcome recorded |
| Phase 3 | NCT03632135 | May 2018 → Jun 2022 | glioblastoma | Cordgenics, LLC | Completed | Met primary |
| Phase 3 | NCT01290939 | Oct 2011 → Oct 2015 | cognitive disorder, glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 3 | NCT01149109 | Oct 2010 → Apr 2017 | glioblastoma | University Hospital, Bonn | Completed | Met primary |
| Phase 3 | NCT00887146 | Sep 2009 → Oct 2029 expected | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00777153 | Oct 2008 → Apr 2010 | glioblastoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00590837 | Feb 2008 → Dec 2012 | acute myeloid leukemia | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00068952 | Aug 2003 → Mar 2006 | glioblastoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00053872 | Feb 2003 → ? | central nervous system neoplasm | University of Leicester | Unknown | No outcome recorded |
| Phase 3 | NCT00052455 | Oct 2002 → Sep 2010 | central nervous system cancer | Institute of Cancer Research, United Kingdom | Completed | Missed primary |
| Phase 3 | NCT00003603 | Mar 1998 → ? | plasma cell myeloma | Riverside Haematology Group | Unknown | No outcome recorded |
| Phase 3 | NCT00002944 | Apr 1997 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00002875 | Dec 1996 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002840 | Aug 1996 → Mar 2002 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT00480064 | Jul 1995 → May 2007 | acute myeloid leukemia | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 3 | NCT00002569 | Jul 1994 → Feb 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase not applicable5 trials | ||||||
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02333513 | Feb 2015 → Dec 2017 | malignant glioma | Hebei Yanda Hospital | Unknown | No outcome recorded |
| — | NCT00317408 | Apr 2004 → Feb 2014 | lymphoma | European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma | Unknown | No outcome recorded |
| — | NCT00058370 | Feb 2003 → Jun 2019 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00303810 | Jan 2001 → Dec 2013 | central nervous system neoplasm | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Comparator or background therapy41 trials | ||||||
| Phase 1 | NCT07629089 Background | Jun 2026 → Jun 2030 expected | brain cancer | Megan Mantica | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00503204 Background | Sep 2007 → Dec 2008 | brain neoplasm, glioblastoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT03382977 Comparator | Dec 2017 → Jul 2025 | glioblastoma | VBI Vaccines Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00948389 Comparator | Oct 2009 → May 2011 | glioblastoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT06816134 Comparator | Jan 2025 → Jan 2028 expected | acute lymphoblastic leukemia, acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06325683 Comparator | Nov 2024 → Jul 2028 | glioblastoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2 | NCT06177964 Comparator | Jul 2024 → Feb 2029 expected | glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 2 | NCT04402073 Background | Nov 2022 → Jun 2025 | medulloblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04933942 Background | Sep → Dec 2022 | high grade astrocytic tumor | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04762069 Comparator | May 2021 → Apr 2026 overdue | adult glioblastoma | CNS Pharmaceuticals, Inc. | Active not recruiting | Missed primary |
| Phase 2 | NCT02926222 Comparator | Nov 2015 → Jul 2017 | glioblastoma | Veneto Institute of Oncology IRCCS | Completed | Met primary |
| Phase 2 | NCT02343406 Comparator | Feb 2015 → Jun 2019 | glioblastoma | AbbVie | Completed | Missed primary |
| Phase 2 | NCT01860638 Background | Aug 2013 → Jan 2017 | glioblastoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT05898451 Background | Jun 2009 → Nov 2011 | cancer | Refnot-Pharm Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00504660 Comparator | Sep 2003 → Aug 2010 | brain cancer, glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00431561 Comparator | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT03970447 Comparator | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | Missed primary |
| Phase 2/3 | NCT03758014 Comparator | Nov 2018 → Oct 2020 | glioblastoma | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | Unknown | No outcome recorded |
| Phase 2/3 | NCT03025893 Comparator | Aug 2018 → Jan 2022 | adult glioblastoma, brain glioma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 2/3 | NCT02678975 Background | Jan 2017 → Jan 2021 | glioblastoma | Sahlgrenska University Hospital | Completed | Missed primary |
| Phase 2/3 | NCT02414165 Comparator | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | Missed primary Stop: Business |
| Phase 3 | NCT05904119 Background | Mar 2024 → Sep 2027 expected | glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT05902169 Comparator | Jan 2024 → Jan 2028 expected | glioblastoma | CarThera | Recruiting | No outcome recorded |
| Phase 3 | NCT05382338 Background | Feb 2023 → Dec 2029 expected | childhood medulloblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05326464 Background | Oct 2022 → Feb 2025 | glioblastoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04702581 Background | Dec 2021 → Dec 2030 expected | oligodendroglioma | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 3 | NCT03149575 Comparator | Oct 2017 → May 2019 | brain cancer, glioblastoma | DelMar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02796261 Comparator | Jul 2016 → Jun 2023 | anaplastic astrocytoma | Orbus Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT02444000 Background | Sep 2015 → Oct 2022 | malignant glioma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00761280 Comparator | Dec 2008 → Feb 2012 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00295815 Comparator | Jan 2006 → Aug 2007 | glioblastoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT00085735 Background | Apr 2004 → Mar 2016 | medulloblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00278278 Background | Sep 2003 → Mar 2010 | central nervous system neoplasm | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| Phase 3 | NCT00700544 Background | Jun 2002 → Apr 2005 | acute myeloid leukemia | University Hospital, Grenoble | Completed | Met primary |
| Phase 3 | NCT00004259 Comparator | Jun 2000 → Feb 2015 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00003788 Background | Apr 1998 → ? | central nervous system cancer | Colorado Health Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT00925873 Comparator | Jun 1996 → Apr 2000 | acute myeloid leukemia | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 4 | NCT05518383 Background | May 2022 → May 2025 overdue | Burkitt lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
| — | NCT05410301 Background | Apr 2023 → Aug 2026 | glioblastoma | Varun Monga, MD | Withdrawn | No outcome recorded |
| — | NCT05667402 Comparator | Jan 2023 → Dec 2025 | central nervous system leukemia, disease related to hematopoietic stem cell transplant | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02076152 Background | Feb 2014 → Apr 2019 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | CNS Pharmaceuticals, Inc. | Results CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme cnspharma.com ↗
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. |
| 2024-11-25 | CNS Pharmaceuticals, Inc. | Results CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy cnspharma.com ↗
The data presented at the SNO Annual Meeting include comparative demographics, disposition of patients, MGMT promoter methylation status and safety, showing that the balance between the randomized arms has been maintained through enrollment of 239 patients into the study. |
| 2024-04-03 | VBI Vaccines Inc. | Results VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma vbivaccines.com ↗
No tumor responses have been observed in the SoC arm |
| 2023-11-22 | CNS Pharmaceuticals, Inc. | Results CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy cnspharma.com ↗
The data presented at the SNO Annual Meeting show the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent GBM. |
| 2023-05-26 | Philogen S.p.A. | Results Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich philogen.com ↗
The study demonstrated that the combination Fibromun and lomustine was highly synergistic and relied on an intact immune system. |
| 2022-12-01 | Philogen S.p.A. | Results Philogen provides corporate update philogen.com ↗
Fibromun shows potent activity in last-line glioblastoma in combination with Lomustine |
| 2021-11-12 | Philogen S.p.A. | Results Philogen provides Corporate Update philogen.com ↗
Fibromun shows potent activity in last-line glioblastoma in combination with Lomustine |
| 2021-07-02 | Philogen S.p.A. | Results Philogen Announces R&D Program Update philogen.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 119 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lomustine | “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗100“Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.” NCT02066220 ↗ “Induction therapy included idarubicin 8 mg/m2 on days 1 to 5, cytarabine 100 mg/m2 on days 1 to 7, and lomustine 200 mg/m2 on day 1.” PMID 28129526 ↗ Oct 2016 “Regimen A: Patients receive oral lomustine and cisplatin on day 0 and vincristine on days 0, 7, and 14” NCT00031590 ↗ “Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,” NCT05331521 ↗ “and Dacarbazine, Lomustine, Cisplatin” NCT05898451 ↗ “lomustine (CCNU), PCV or temozolomide” NCT02678975 ↗ “Lapatinib, Lomustine, Mechlor” NCT02788201 ↗ “Lapatinib Lomustine Melphalan” NCT02551718 ↗ |
| Known as | BCNU | “Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin” NCT05518383 ↗ |
| Known as | CCNU | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗26“A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and...” NCT02765165 ↗ “mBuCy conditioning regimen（CCNU 250mg/m2/d -9d, Ara-C 2g/m2/d -8d; CDA 5 mg/m2/d -8d; Busulfan 3.2 mg/kg/d from -7 to -5 days; Cyclophosphamide 1.8 mg/m2/d from -4 to -3 days）” NCT06816134 ↗ “The impact of combined procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy after radiotherapy (RT) compared with RT alone” PMID 18089866 ↗ Dec 2007 “patients received lomustine (CCNU) plus BEV (CCNU + BEV) or CCNU plus placebo (CCNU + placebo) until further disease progression (PD2).” PMID 30266892 ↗ Sep 2018 “The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.” NCT05667402 ↗ “temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen” NCT00431561 ↗ “procarbazine, lomustine (CCNU), and vincristine (PCV) is active in patients with recurrent LGO/LGOA” PMID 12525516 ↗ Jan 2003 “The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.” NCT03149575 ↗ “Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade glioma” NCT03463265 ↗ “procarbazine, lomustine (also called CCNU), and vincristine” PMID 27050206 ↗ Apr 2016 |
| Known as | CeeNu | “Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy.” NCT03758014 ↗1“The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.” NCT03149575 ↗ |
| Known as | Gleostine | “Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy.” NCT03758014 ↗ |
| Known as | Lomustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL514 ↗ |
| Known as | lomustine (CCNU) | “lomustine (CCNU)” NCT03463265 ↗ |
| Known as | NSC-79037 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514 ↗ |
| Modality | Small molecule | “Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents.” NCT00777153 ↗ |
| Route | Oral | “oral lomustine on day 1” NCT00002569 ↗ |